Cohen, A. T., Harrington, R., Goldhaber, S. Z., Hull, R., Gibson, C. M., Hernandez, A. F., & Gold, A. (2015). Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. Am Heart J, 169(1), 186–187. https://doi.org/10.1016/j.ahj.2014.09.004

Cohen, Alexander T., Robert Harrington, Samuel Z. Goldhaber, Russell Hull, C. M. Gibson, Adrian F. Hernandez, and Alex Gold. “Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment.” Am Heart J 169, no. 1 (January 2015): 186–87. https://doi.org/10.1016/j.ahj.2014.09.004.

Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, et al. Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. Am Heart J. 2015 Jan;169(1):186–7.

Cohen, Alexander T., et al. “Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment.” Am Heart J, vol. 169, no. 1, Jan. 2015, pp. 186–87. Pubmed, doi:10.1016/j.ahj.2014.09.004.

Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, Gold A. Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. Am Heart J. 2015 Jan;169(1):186–187.